1645-32-5

Basic information

• Product Name: N-desmethylquazepam
• Synonyms: N-desmethylquazepam
• CAS NO: 1645-32-5
• Molecular Formula: C₁₅H₁₀ClFN₂S
• Molecular Weight: 304.7697032
• Mol File: 1645-32-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 410.2°Cat760mmHg
• Flash Point: 201.9°C
• Appearance: /
• Density: 1.39g/cm³
• Vapor Pressure: 6.12E-07mmHg at 25°C
• Refractive Index: 1.671
• PKA: 9.55±0.40(Predicted)
• CAS DataBase Reference: N-desmethylquazepam(CAS DataBase Reference)
• NIST Chemistry Reference: N-desmethylquazepam(1645-32-5)
• EPA Substance Registry System: N-desmethylquazepam(1645-32-5)

Safety Data

• Hazardous Substances Data: 1645-32-5(Hazardous Substances Data)

Usage

Description

N-desmethylquazepam is a chemical compound and an active metabolite of the benzodiazepine drug quazepam. It is formed in the body through the process of N-demethylation, where one of the methyl groups on the quazepam molecule is removed. This metabolite is believed to contribute to the pharmacological effects of quazepam, including its sedative and anxiolytic properties. N-desmethylquazepam is also likely to have a longer half-life than quazepam itself, as it is a metabolite that may undergo further metabolism before being excreted from the body. Furthermore, it may play a role in the potential for drug interactions and side effects associated with quazepam use.

Uses

Used in Pharmaceutical Industry:
N-desmethylquazepam is used as a metabolite of quazepam for its contribution to the sedative and anxiolytic effects of the parent drug. Its longer half-life compared to quazepam may influence the duration of action and the potential for side effects and drug interactions. This makes it an important compound to consider in the development and assessment of benzodiazepine medications and their metabolites for therapeutic use.

InChI:InChI=1/C15H10ClFN2S/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)

Upstream product

• 784-38-3 2-amino-5-chloro-2'-fluorobenzophenone 
• 393-52-2 2-Fluorobenzoyl chloride 
• 106-47-8 4-chloro-aniline 
• 1584-62-9 2?(2?bromoacetamido)?5?chloro?2'?fluorobenzophenone 
• 2836-40-0 2-(2-chloroacetyl)amino-4-chloro-2'-fluorobenzophenone 
• 2886-65-9 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2(2H)-one 

Downstream Products

• 59467-61-7 7-chloro-5-(2-fluorophenyl)-3H-1,4-benzodiazepine-2-methylamine 
• 1255209-68-7 C₁₇H₁₂ClFN₂S 
• 28910-91-0 flualprazolam 
• 819793-80-1 8?chloro?6?(2?fluorophenyl)?1?methyl?3?(4?toluenesulfonyl)?4H?imidazo[1,5?a][1,4]benzodiazepine 
• 819793-75-4 8?chloro?6?(2?fluorophenyl)?3?(4?toluenesulfonyl)?4H?imidazo[1,5?a][1,4]benzodiazepine 
• 59467-62-8 7-chloro-5-(2-fluorophenyl)-2-(N-nitrosomethylamino)-3H-1,4-benzodiazepine 

Relevant articles and documents

Synthesis of?some?new substituted triazolo [4,3-a][1,4] benzodiazepine derivatives as?potent anticonvulsants

Novel 8-chloro-6-(2-fluorophenyl)-1-(aryl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines (5a-f) were prepared by treating 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-thione with various aromatic acid hydrazides. The newly prepared compounds were characterized by spectral analysis. Compounds were tested for anticonvulsant activity. Four of the tested compounds such as 5a, 5d, 5e and 5f exhibited excellent anticonvulsant activity in comparison with standard drug, diazepam.

Preparation method of 7-chloro-5-(2-fluorophenyl)-3H-1, 4-benzodiazepin-2-methylamine

The invention provides a preparation method of 7-chloro-5-(2-fluorophenyl)-3H-1, 4-benzodiazepin-2-methylamine, which comprises the following steps: (1) reacting 7-chloro-5-(2-fluorophenyl)-1, 3-dihydro-2H-1, 4-benzodiazepin-2-one with phosphorus pentasulfide to obtain 7-chloro-5-(2-fluorophenyl)-1, 3-dihydro-2H-1, 4-benzodiazepin-2-thione, and (2) enabling the 7-chloro-5-(2-fluorophenyl)-1, 3-dihydro-2H-1, 4-benzodiazepin-2-thione to react with a methylamine alcohol solution, so as to prepare the 7-chloro-5-(2-fluorophenyl)-3H-1, 4-benzodiazepin-2-methylamine. The preparation method providedby the invention is low in cost, mild in condition, safe in production, high in yield, stable and reliable in product quality, simple and convenient to operate and more suitable for industrial production.

PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM

The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-brain barrier. The compounds and compositions of the present invention are useful for treatment of diseases or disorders which are mediated by GABA-A neuronal activity, such as, for example, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance.